Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran

Karimi, A. and Salimzadeh, L. and Bagheri, N. (2014) Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran. JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 7 (4).

[img]
Preview
Text
48.pdf

Download (634kB) | Preview

Abstract

Background: Hepatitis B infection, caused by hepatitis B Virus (HBV), is one of the major global public health problems. Hepatitis B Virus genotypes appear to show varying geographic distribution with possible pathogenic and therapeutic differences. Knowledge of HBV genotypes is very important for clinical treatment. Lamivudine is a nucleoside analogue that is clinically used to treat chronic hepatitis B infection. However, the main problem with the application of lamivudine is the development of viral resistance to the treatment with this anti viral drug. Besides, it has been suggested that lamivudine-resistant HBV may be genotype dependent. However, HBV genotype distribution and the biological relevance in this region are poorly understood. Objectives: The current study aimed to determine hepatitis B genotypes and their correlation with lamivudine-resistant HBV frequency among patients with chronic hepatitis B from Shahrekord, Iran. Methods and Materials: Hepatitis B virus DNA was detected by conventional PCR in some of the serum samples obtained from HBsAg-positive Chronic Hepatitis B (CHB) patients who were referred to Health Centers of Shahrekord for routine monitoring of the disease. Subsequently, using real-time PCR, the DNA samples were used for genotyping and analysis of resistance to lamivudine. Results: The DNA was detected in 23 out of 116 (19.82%) of the studied samples. Genotypes D and C were found in 17 out of 23 (73.9%), and in 6 out of 23 (26.1%) of the samples, respectively. To the authors' best knowledge, the current study is the first report on isolation of Genotype C from Iran. Two out of 17 (11.76%), and 6 out of 6 (100%) of genotypes D and C were resistant to lamivudine, respectively. Resistance to this drug was significantly different between genotypes C and D (P < 0.001). Conclusions: In addition to genotype D, other lamivudine resistant hepatitis B genotypes might be distributed in Iran.

Item Type: Article
Uncontrolled Keywords: Hepatitis B, Chronic; Polymerase Chain Reaction; Genotyping Techniques
Subjects: WC Communicable Diseases > Virus diseases
WK Endocrine System
QV pharmacology > QV 704 Pharmaceutics
Divisions: Reserach Vice-Chancellar Department > Medical Plants Research Center
Depositing User: zahra bagheri .
Date Deposited: 31 Jul 2017 08:46
Last Modified: 31 Jul 2017 08:46
URI: http://eprints.skums.ac.ir/id/eprint/2127

Actions (login required)

View Item View Item